Barinthus Biotherapeutics PLC Form 4 insider transactions

Barinthus Biotherapeutics and Clywedog Therapeutics have amended their merger agreement, adjusting exchange ratios and minimum cash requirements due to unexpected U.S. federal government shutdowns.

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, operating as Clywedog Therapeutics, Inc.

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, with Clywedog stockholders owning approximately 66%.

Barinthus Biotherapeutics plc Director Alex Hammacher was granted 20,174 share options with an exercise price of $1, aligning his interests with long-term shareholder value.

Barinthus Biotherapeutics plc. Director Robin Wright was granted 20,174 share options with an exercise price of $1, vesting by June 2026 or the next annual meeting, as disclosed in a recent SEC Form 4 filing.

Barinthus Biotherapeutics plc. Director Pierre A. Morgon was granted 20,174 share options with an exercise price of $1, aligning his interests with shareholders.

Barinthus Biotherapeutics plc director Anne M. Phillips was granted 20,174 share options as part of her compensation, vesting based on continued service.

Barinthus Biotherapeutics plc. Director Joseph Scheeren was granted 20,174 share options with an exercise price of $1, vesting by June 2026 or the next annual meeting.

Barinthus Biotherapeutics plc. has granted 20,174 share options to Director Karen A. Dawes, aligning her interests with the company's long-term performance.

Gemma Brown, CFO of Barinthus Biotherapeutics, reports the acquisition of 160,000 share options exercisable over the next ten years.

William Enright, CEO of Barinthus Biotherapeutics plc, reports the acquisition of 600,000 share options exercisable at $1, vesting in three annual installments starting February 3, 2026.

Graham Griffiths, Chief Business Officer of Barinthus Biotherapeutics, receives options to purchase 200,000 ordinary shares.

Leon Hooftman, Chief Medical Officer of Barinthus Biotherapeutics plc, reports the acquisition of 140,000 share options.

Leon Hooftman, Chief Medical Officer of Barinthus Biotherapeutics plc, was granted options to purchase 195,166 ordinary shares on June 3, 2024.

Karen A. Dawes, a director of Barinthus Biotherapeutics plc, acquired share options exercisable for 19,516 ordinary shares on May 10, 2024.

Director Joseph Scheeren acquired options to purchase 19,516 ordinary shares of Barinthus Biotherapeutics plc.

Director Anne M. Phillips acquired share options in Barinthus Biotherapeutics plc.

Director Alex Hammacher acquired options to purchase 19,516 ordinary shares of Barinthus Biotherapeutics plc. on May 10, 2024.

Director Pierre A. Morgon acquired options to purchase 19,516 ordinary shares of Barinthus Biotherapeutics plc. on May 10, 2024.

Director Robin Wright acquired share options in Barinthus Biotherapeutics, vesting in full by May 10, 2025, or the next annual shareholder meeting.